Clinical Trial Update: Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma [Phase 1]

View source ↗

Summary

An exploratory Phase 1 trial is evaluating umbilical cord blood–derived CAR-NK cells targeting TRBC1/2 in patients with relapsed or refractory peripheral T-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Cord blood-derived CAR-NK cell therapy targeting TRBC1/2

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Refractory/Recurrent Peripheral T-cell Lymphoma | Phase 1 | Status: RECRUITING